Drug intelligence / Profile preview

azithromycin + piperacillin-tazobactam

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

This is a combination antibiotic therapy consisting of azithromycin (a macrolide antibiotic) and piperacillin-tazobactam (a penicillin antibiotic with beta-lactamase inhibitor). The combination is used to treat various bacterial infections, particularly community-acquired pneumonia. Piperacillin works by killing bacteria through preventing cell wall formation, while tazobactam prevents bacteria from destroying piperacillin. Azithromycin works through a different mechanism, making this a multi-mechanism approach to treating bacterial infections.

Other names: azithromycin + Zosyn

Targets

Class A BL (Class A beta-lactamase)Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on azithromycin + piperacillin-tazobactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + piperacillin-tazobactam.

Explore the full profile